Profound chemopreventative effects of a hydrogen sulfide-releasing nsaid in the APCMin/+ mouse model of intestinal tumorigenesis

PLoS ONE

Volumn 11, Issue 2, 2016, Pages

  Paul Clark, Mark ^a   Elsheikh, Wagdi ^b   Kirkby, Nicholas ^a   Chan, Melissa ^c   Devchand, Pallavi ^d   Agbor, Terence A ^b   Flannigan, Kyle L ^b   Cheadle, Charlotte ^a   Freydin, Maxim ^b   Ianaro, Angela ^e   Mitchell, Jane A ^a   Wallace, John L ^f,g  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b MCMASTER UNIVERSITY   (Canada)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^d MOUNT SINAI HOSPITAL   (United States)

^e UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^f UNIVERSITY OF CALGARY   (Canada)

^g UNIVERSIDADE CAMILO CASTELO BRANCO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

2 (6 METHOXYNAPTHALEN 2 YL)PROPIONIC ACID 4 THIOCARBAMOYLPHENYL ESTER; APC PROTEIN; BETA CATENIN; HYDROGEN SULFIDE; MYC PROTEIN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; UNCLASSIFIED DRUG; 2-(6-METHOXY-NAPTHALEN-2-YL)-PROPIONIC ACID 4-THIOCARBAMOYL-PHENYL ESTER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER PREVENTION; CONTROLLED STUDY; INTESTINE POLYP; INTESTINE TUMOR; MALE; MOUSE; MOUSE MODEL; NONHUMAN; TRANSCRIPTOMICS; ANALOGS AND DERIVATIVES; ANIMAL; C57BL MOUSE; CARCINOGENESIS; CHEMISTRY; CHEMOPROPHYLAXIS; COLON; DRUG EFFECTS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; INTESTINAL NEOPLASMS; INTESTINAL POLYPS; METABOLISM; PATHOLOGY;

ADENOMATOUS POLYPOSIS COLI PROTEIN; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BETA CATENIN; CARCINOGENESIS; CHEMOPREVENTION; COLON; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HYDROGEN SULFIDE; INTESTINAL NEOPLASMS; INTESTINAL POLYPS; MALE; MICE; MICE, INBRED C57BL; NAPROXEN; PROTO-ONCOGENE PROTEINS C-MYC;

EID: 84962503611     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0147289     Document Type: Article

References (51)

1. http://seer.cancer.gov/statfacts/html/colorect.html
2. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008;454:436-444. doi: 10.1038/nature07205 PMID: 18650914
3. Moser AR, Pitot HC, Dove WF. A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse. Science 1990;247:322-324. PMID: 2296722
4. Logan RF, Little J, Hawtin PG, Hardcastle JD. Effect of aspirin and non-steroidal anti-inflammatory drugs on colorectal adenomas: case-control study of subjects participating in the Nottingham faecal occult blood screening programme. BMJ 1993;307:285-289. PMID: 8374373
5. Sandler RS, Halabi S, Baron JA, Budinger S, Paskett E, Keresztes R, et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. New Engl J Med. 2003;348:883-890. PMID: 12621132
6. Iwama T. NSAIDs and colorectal cancer prevention. J Gastroenterol. 2009;44 Suppl1:72-76.
7. Kudo T, Narisawa T, Abo S. Antitumor activity of indomethacin on methylazoxymethanol-induced large bowel tumors in rats. Gan. 1980;71, 260-264. PMID: 7202921
8. Kishimoto Y, Yashima K, Morisawa Y, Shiota G, Kawasaki H, Hasegawa J. Effects of cyclooxygenase-2 inhibitor NS-398 on APC and c-myc expression in rat colon carcinogenesis induced by azoxymethane. J Gasteroenterol. 2002;37:186-193.
9. Wallace JL. Mechamisms, prevention and clinical implications of nonsteroidal anti-inflammatory drugenteropathy. World J Gastroenterol. 2013;19:1861-1876. doi: 10.3748/wjg.v19.i12.1861 PMID: 23569332
10. Wallace JL. Polypharmacy of osteoarthritis: the perfect intestinal storm. Dig Dis Sci. 2013;58:3088-3093. doi: 10.1007/s10620-013-2777-8 PMID: 23884755
11. Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. Br Med J. 2006;332:1302-1308.
12. Wallace JL, Wang R. Hydrogen sulfide-based therapeutics: exploiting a unique but ubiquitous gasotransmitter. Nat Rev Drug Discov. 2015;14:329-345. doi: 10.1038/nrd4433 PMID: 25849904
13. Kimura H, Shibuya N, Kimura Y. Hydrogen sulfide is a signalling molecule and a cytoprotectant. Antioxid Redox Signal 2012;17:45-57. doi: 10.1089/ars.2011.4345 PMID: 22229673
14. Whiteman M, Armstrong JS, Chu SH, Jia-Ling S, Wong BS, Cheung NS, et al. The novel neuromodulator hydrogen sulfide: An endogenous peroxynitrite 'scavenger'? J Neurochem. 2004;90:765-768. PMID: 15255956
15. Whiteman M, Cheung NS, Zhu YZ, Chu SH, Siau JL, Wong BS, et al. Hydrogen sulphide: a novel inhibitor of hypochlorous acid-mediated oxidative damage in the brain? Biochem Biophys Res Commun. 2005;326:794-798. PMID: 15607739
16. Pálinkás Z, Furtmüller PG, Nagy A, Jakopitsch C, Pirker KF, Magierowski M, et al. Interactions of hydrogen sulfide with myeloperoxidase. Br J Pharmacol. 2015;172:1516-1532. doi: 10.1111/bph.12769 PMID: 24824874
17. Li L, Rossoni G, Sparatore A, Lee LC, Del Soldato P, Moore PK. Anti-inflammatory and gastrointestinal effects of a novel diclofenac derivative. Free RadicBiol Med. 2007;42:706-719. PMID: 17291994
18. Mustafa AK, Gadalla MM, Sen N, Kim S, Mu W, Gazi SK, et al. H2S signals through protein S-sulfhydration. Sci Signal. 2009;2:ra72. doi: 10.1126/scisignal.2000464 PMID: 19903941
19. Yang G, Zhao K, Ju Y, Mani S, Cao Q, Puukila S, et al. Hydrogen sulfide protects against cellular senescence via S-sulfhydration of Keap1 and activation of Nrf2. Antioxid Redox Signal. 2013;18:1906-1919. doi: 10.1089/ars.2012.4645 PMID: 23176571
20. Fiorucci S, Orlandi S, Mencarelli A, Caliendo G, Santagada V, Distrutti E, et al. Enhanced activity of a hydrogen sulphide-releasing derivative of mesalamine (ATB-429) in a mouse model of colitis. Br J Pharmacol. 2007;150:996-1002. PMID: 17339831
21. Flannigan KL, Agbor TA, Motta JP, Ferraz JG, Wang R, Buret AG, et al. Proresolution effects of hydrogen sulfide during colitis are mediated through hypoxia-inducibefactor-1a. FASEB J. 2015;29:1591-1602. PMID: 25550470
22. Wallace JL, Dicay M, McKnight W, Martin GR. Hydrogen sulfide enhances ulcer healing in rats. FASEB J, 2007;21:4070-4076. PMID: 17634391
23. Wallace JL, Vong L, McKnight W, Dicay M, Martin GR. Endogenous and exogenous hydrogen sulfide promotes resolution of colitis in rats. Gastroenterology 2009;137, 569-578. doi: 10.1053/j.gastro. 2009.04.012 PMID: 19375422
24. Whiteman M, Winyard PG. Hydrogen sulfide and inflammation: the good, the bad, the ugly and the promising. Expert Rev Clin Pharmacol. 2011;4:13-32. doi: 10.1586/ecp. 10.134 PMID: 22115346
25. Wallace JL, Caliendo G, Santagada V, Cirino G. Markedly reduced toxicity of a hydrogen sulphidereleasing derivative of naproxen (ATB-346). Br J Pharmacol 2010;159:1236-1246. doi: 10.1111/j. 1476-5381.2009.00611.x PMID: 20128814
26. Wallace JL, Caliendo G, Santagada V, Cirino G, Fiorucci S. Gastrointestinal safety and anti-inflammatory effects of a hydrogen sulfide-releasing diclofenac derivative in the rat. Gastroenterology 2007;132:261-271. PMID: 17241876
27. Chattopadhyay M, Kodela R, Nath N, Dastagirzada YM, Velázquez-Martínez CA, Boring D, et al. Hydrogen sulfide-releasing NSAIDs inhibit the growth of human cancer cells: A general property and evidence of a tissue type-independent effect. Biochem Pharmacol, 2012;83:715-722. doi: 10.1016/j. bcp. 2011.12.018 PMID: 22222427
28. Chattopadhyay M, Kodela R, Olson KR, Kashfi K. NOSH-aspirin (NBS-1120), a novel nitric oxide- and hydrogen sulfide-releasing hybrid is a potent inhibitor of colon cancer cell growth in vitro and in a xenograft mouse model. Biochem Biophys Res Commun. 2012;419:523-528. PMID: 22366248
29. Kashfi K. Anti-cancer activity of new designer hydrogen sulfide-donating hybrids. Antioxid Redox Signal. 2014;20:831-846. doi: 10.1089/ars.2013.5308 PMID: 23581880
30. Elsheikh W, Blackler RW, Flannigan KL, Wallace JL. Enhanced chemopreventive effects of a hydrogen sulfide-releasing anti-inflammatory drug (ATB-346) in experimental colorectal cancer. Nitric Oxide 2014;41:131-137. PMID: 24747869
31. Tetsu O, McCormick F. (5-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 1999;398:422-426. PMID: 10201372
32. Fijneman RJ, Anderson RA, Richards E, Liu J, Tijssen M, Meijer GA, et al. Runx1 is a tumor suppressor gene in the mouse gastrointestinal tract. Cancer Sci. 2012;103:593-599. doi: 10.1111/j.1349-7006. 2011.02189.x PMID: 22171576
33. Chorley BN, Campbell MR, Wang X, Karaca M, Sambandan D, Bangura F, et al. Identification of novel NRF2-regulated genes by ChIP-Seq: influence of retinoid X receptor alpha. Nucleic Acids Res. 2012;40:7416-7429. doi: 10.1093/nar/gks409 PMID: 22581777
34. Jaramillo MC, Zhang DD. The emerging role of the Nrf2-Keap1 signaling pathway in cancer. Genes Dev. 2013;27:2179-2191. PMID: 24142871
35. Gemici B, Elsheikh W, Feitosa KB, Costa SK, Muscara MN, Wallace JL. H2S-releasing drugs: antiinflammatory, cytoprotective and chemopreventative potential. Nitric Oxide 2015;46:25-31. doi: 10. 1016/j.niox.2014.11.010 PMID: 25461269
36. Blackler R, Syer S, Bolla M, Ongini E, Wallace JL. Gastrointestinal-sparing effects of novel NSAIDs in rats with compromised mucosal defence. PLoSOne 2012;7:e35196. doi: 10.1371/journal.pone. 0035196 PMID: 22496907
37. Farrugia G, Balzan R. The proapoptotic effect of traditional and novel nonsteroidal anti-inflammatory drugs in mammalian and yeast cells. Oxid Med Cell Longev. 2013:504230. doi: 10.1155/2013/504230 PMID: 23983899
38. Wallace JL, Cirino G, Santagada V, Caliendo G. Hydrogen sulfide derivatives of nonsteroidal antiinflammatory drugs. United States Patent Application No. WO/2008/009127.
39. Solomon SD, Pfeffer MA, McMurray JJ, Fowler R, Finn P, Levin B, et al. Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas. Circulation 2006;114:1028-1035. PMID: 16943394
40. Zhu Y, Liu X, Sköld CM, Wang H, Kohyama T, Wen FQ, et al. Collaborative interactions between neutrophil elastase and metalloproteinases in extracellular matrix degradation in three-dimensional collagen gels. Respir Res 2001;2:300-305. PMID: 11686900
41. Teicher BA, Tomaszewski JE. Proteasome inhibitors. Biochemical Pharmacol. 2015;96:1-9.
42. Yang G, Li H, Tang G, Wu L, Zhao K, Cao Q, et al. Increased neointimalformation in cystathionine gamma-lyase deficient mice: role of hydrogen sulfide in a5p1-integrin and matrix metalloproteinase-2 expression in smooth muscle cells. J Mol Cell Cardiol. 2012;52:677-688. PMID: 22200376
43. Rechreche H, Montalto G, Mallo GV, Vasseur S, Marasa L, Soubeyran P, et al. PAP, reg Ialphaand reg Ibeta mRNAs are concomitantly up-regulated during human colorectal carcinogenesis. Int J Cancer 1999;81:688-694. PMID: 10328217
44. Macadam RC, Sarela AI, Farmery SM, Robinson PA, Markham AF, Guillou PJ. Death from early colorectal cancer is predicted by the presence of transcripts of the REG gene family. Br J Cancer 2000;83:188-195. PMID: 10901369
45. Valladares-Ayerbes M, Diaz-Prado S, Reboredo M, Medina V, Iglesias-Diaz P, Lorenzo-Patino MJ, et al. Bioinformatics approach to mRNA markers discovery for detection of circulating tumor cells in patients with gastrointestinal cancer. Cancer Detect Prevention 2008;32:236-250.
46. Seyama K, Nukiwa T, Takahashi K, Takahashi H, Kira S. Amylase mRNA transcripts in normal tissues and neoplasms: the implication of different expressions of amylase isogenes. J Canc Res Clin Oncol. 1994;120:213-220.
47. Wiese AH, Auer J, Lassmann S, Nährig J, Rosenberg R, Höfler H, et al. Identification of gene signatures for invasive colorectal tumor cells. Cancer Detect. Prevent. 2007;31:282-295. PMID: 17936523
48. Narushima Y, Unno M, Nakagawara K, Mori M, Miyashita H, Suzuki Y, et al. Structural chromosomal localization and expression of mouse genes encoding type III Reg, RegIII alpha, RegIII beta, RegIII gamma. Gene 1997;185:159-168. PMID: 9055810
49. Barnett MPG, McNabb WC, Cookson AL, Zhu S, Davy M, Knoch B, et al. Changes in colon gene expression associated with increased colon inflammation in interleukin-10 gene-deficient mice inoculated with Enterococcus species. BMC Immunol. 2010;11:39. doi: 10.1186/1471-2172-11-39 PMID: 20630110
50. Wallace JL, Syer S, Denou E, de Palma G, Vong L, McKnight W, et al. Proton pump inhibitors exacerbate NSAID-induced small intestinal injury by inducing dysbiosis. Gastroenterology 2011;141:1314-1322. doi: 10.1053/j.gastro.2011.06.075 PMID: 21745447
51. Watanabe T, Higuchi K, Kobata A, Nishio H, Tanigawa T, Shiba M, et al. Non-steroidal anti-inflammatory drug-induced small intestinal damage is Toll like receptor 4 dependent. Gut 2008;57:181-187. PMID: 17639086